ライフサイエンスコーパス: de-escalation

1 ided planned surgery and radiotherapy (total de-escalation).

2 cy in patients at high risk of bleeding (ie, de-escalation).

3 microbial stewardship enhanced antimicrobial de-escalation.

4 and a positive PCR result had antimicrobial de-escalation.

5 resistant Gram-negative bacteria followed by de-escalation.

6 h cohorts at the starting dose required dose de-escalation.

7 ctDNA is for adjuvant therapy escalation and de-escalation.

8 ng on strategies for treatment escalation or de-escalation.

9 ures, the guidelines recommend antimicrobial de-escalation.

10 nd feasibility of response-guided escalation/de-escalation.

11 lows the opportunity for (chemo)radiotherapy de-escalation.

12 ng the potential for tailored treatments and de-escalation.

13 quamous cell carcinoma (OPSCC) for treatment de-escalation.

14 isms, but usually did not lead to antibiotic de-escalation.

15 ococcal infection would allow for antibiotic de-escalation.

16 ned inflammatory toxicities, leading to dose de-escalation.

17 ococcal infection would allow for antibiotic de-escalation.

18 y is needed to obtain favorable results with de-escalation.

19 isms, but usually did not lead to antibiotic de-escalation.

20 from BSA varied more than 2-fold (anti-MRSA de-escalation, 27.3% to 61.7%; anti-PSA de-escalation, 6

21 MRSA de-escalation, 27.3% to 61.7%; anti-PSA de-escalation, 6.9% to 37.7%).

22 eltamivir in infants aged <2 years in an age-de-escalation, adaptive design with a targeted systemic

23 Antimicrobial de-escalation (ADE) is a strategy to reduce the spectrum

24 d potential correlates of AAM escalation and de-escalation after CTO PCI.

25 II trial testing an aggressive course of RT de-escalation after surgery.

26 th R/R-AML using a 3 + 3 dose escalation and de-escalation algorithm for identification of maximum to

27 ening may be a powerful stewardship tool for de-escalation and avoidance of empirical anti-MRSA thera

28 ty of axillary management, and any policy of de-escalation and avoidance of morbidity must not compro

29 Patients were propensity adjusted for de-escalation and compared on in-hospital 14-day mortali

30 alization of therapy as well as at treatment de-escalation and escalation based on tumour biology and

31 Critical care had higher rates of both de-escalation and escalation compared with wards.

32 this study were to investigate predictors of de-escalation and its impact on the outcome of patients

33 for selecting appropriate patients, defining de-escalation and monitoring modalities and outlining un

34 rived an electronic definition of antibiotic de-escalation and performed a retrospective study among

35 se KKIN PCR facilitated timely antimicrobial de-escalation and potentially contributed to shortened h

36 s the proportion of patients who lost MMR on de-escalation and regained MMR on TKI resumption.

37 The De-Escalation and Stopping Treatment with Imatinib, Nilo

38 ning patients who are candidates for therapy de-escalation), and not in Group 3 or SHH.

39 associations of UAT results with antibiotic de-escalation, and associations of de-escalation with ou

40 associations of UAT results with antibiotic de-escalation, and associations of de-escalation with ou

41 mmon interventions for self harm were verbal de-escalation, and manual restraint.

42 time to appropriate antibiotic escalation or de-escalation, and secondary outcomes included time to o

43 A standard, objective definition of de-escalation applied to electronic data could be useful

44 vents without any trade-off in safety, and a de-escalation approach associated with a significant red

45 re has been a shift to a procedural conflict de-escalation approach to addressing clinical questions

46 Several de-escalation approaches are under investigation in pati

47 e assess the economic impact of implementing de-escalation approaches.

48 echanical circulatory support escalation and de-escalation are limited.

49 frequencies of UAT and subsequent antibiotic de-escalation are unknown.

50 Studies of more ambitious de-escalation are warranted.

51 We aimed to examine the effects of treatment de-escalation as a prelude to complete cessation, not on

52 reening maybe used as a stewardship tool for de-escalation as well as avoidance of anti-MRSA therapy.

53 rt-course treatment regimens and the use of 'de-escalation' as a strategy for antibiotic prescribing.

54 De-escalation attempts occurred by ED staff for 29 patie

55 Theme 3 was that de-escalation attempts were not well documented.

56 re considering treatment alterations such as de-escalation based on histopathology.

57 Initial de-escalation before discontinuation might improve the s

58 Age de-escalation between cohorts was based on the review of

59 All 5 patients who underwent dose de-escalation, but neither of the control patients, expe

60 m was to confirm noninferiority of treatment de-escalation by omission of bleomycin from doxorubicin,

61 The workshop also addressed the issue of de-escalation by the type of DMT used and in specific si

62 roposed by the Academic Research Consortium, de-escalation can be achieved by discontinuation of 1 an

63 Results of this phase 1 dose de-escalation case series study revealed that bevacizuma

64 SETTING, AND PARTICIPANTS: This phase 1 dose de-escalation case series study was conducted at 10 US h

65 early-stage breast cancer using neoadjuvant de-escalation chemotherapy with paclitaxel, trastuzumab,

66 trolled, open-label, curative-intent therapy de-escalation clinical trial in adults with stage I, II,

67 Because of dose-limiting toxicities, a de-escalation cohort (10 mg lenalidomide) was initiated,

68 No DLTs were observed in the subsequent dose-de-escalation cohort, establishing the MTD and recommend

69 bacteremia with electronic isolate-specific de-escalation comments and daytime antibiotic stewardshi

70 -negative resistance were associated with BL de-escalation compared to no-change (hazards ratio (HR)

71 hat use genotypic RDTs to inform therapeutic de-escalation decisions should be aware of the incidence

72 500 mg twice daily in a standard 3 + 3 dose de-escalation design.

73 Median time to any antibiotic de-escalation did not differ between groups (p=0.37).

74 ram-positive bacteria, and faster antibiotic de-escalations directed at Gram-positive bacteria.

75 We conducted an age de-escalation, dose-escalation randomized controlled tri

76 terature to identify studies reporting after de-escalation (drug cessation or dose reduction) of anti

77 we analyzed findings from 69 studies (18 on de-escalation [drug cessation or dose reduction] of immu

78 There were two dose de-escalations due to neurotoxicity on this or other stu

79 sed to analyze factors associated with early de-escalation (EDE) and Cox regression for the impact of

80 XT is imperative before any form of axillary de-escalation, especially RLNR omission.

81 l research is needed regarding antimicrobial de-escalation, especially when antibiotics with broad Gr

82 At hospitals in the top quartile of de-escalation, even among patients at lowest risk for mo

83 f PIK3CA, ESR1 or RB1 mutation, also in drug de-escalation experiments or omitting endocrine therapy.

84 tal rate of UAT was strongly correlated with de-escalation following a positive test.

85 The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron e

86 ults further support the benefit of surgical de-escalation for low-risk cervical cancer.

87 2 clinical trial demonstrated that treatment de-escalation for patients with high-risk stage II color

88 d, with protocol-directed dose-escalation or de-escalation for subsequent cohorts.

89 Despite interest in therapy de-escalation for survivors of human papillomavirus-medi

90 rpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvan

91 trospective cohort study evaluated impact of de-escalation from antipseudomonal beta-lactam (APBL) th

92 It also has the potential to enable early de-escalation from broad-spectrum empirical antimicrobia

93 omodulator monotherapy, 8 on immunomodulator de-escalation from combination therapy, and 43 on de-esc

94 he stepwise dual antiplatelet therapy (DAPT) de-escalation group (n=975) consisting of aspirin plus t

95 ed in 87 (8.9%) participants in the stepwise de-escalation group and 84 (8.6%) in the standard group

96 had a dose-limiting toxic effect in the dose de-escalation group receiving FOLFIRINOX plus PF-0413630

97 on-phase group (n=33) with those in the dose de-escalation group that received PF-04136309 at the rec

98 propensity-adjusted analysis, patients with de-escalation had lower odds of subsequent transfer to I

99 This trend for de-escalation has accompanied a shift in understanding o

100 Radiotherapy de-escalation has the potential to improve the therapeut

101 h a trend in decreased time to escalation or de-escalation (hazard ratio, 1.22; 95% confidence interv

102 I, 0.65-0.84) and an increased likelihood of de-escalation (HR, 1.15; 95% CI, 1.02-1.30).

103 improved antimicrobial management, including de-escalation in 11, escalation in 5, and adjustments in

104 N panel result, including discontinuation or de-escalation in 48.2% of patients, resulting in an aver

105 llenge, we evaluated RSV post-F antigen dose de-escalation in BALB/c mice in the presence of a Th1-bi

106 elect patients for response-guided treatment de-escalation in future trials.

107 ysis the resulting theoretical definition of de-escalation in healthcare is "a collective term for a

108 odstream infection incidence coinciding with de-escalation in ICU one, whereas MRSE-BSI incidence dec

109 or, and the potential pitfalls of, treatment de-escalation in MS.

110 olecular testing had the potential to enable de-escalation in number and/or spectrum of antimicrobial

111 De-escalation in patients with monomicrobial bacteremia

112 ing a significant opportunity for antibiotic de-escalation in patients.

113 ta are needed about the safety of antibiotic de-escalation in specific clinical situations as a strat

114 Antibiotic de-escalation in suspected sepsis is infrequent, variabl

115 tion, predictors, and outcomes of antibiotic de-escalation in suspected sepsis.

116 late production; a trend toward evolutionary de-escalation in the numbers and diversity of glucosinol

117 r inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of

118 Predictors of de-escalation included less severe disease on day 3-4, p

119 py, we classified patients into four groups: de-escalation (interruption of an antimicrobial agent or

120 in ICU one, of which 197 occurred before the de-escalation intervention in Feb 1, 2019, and S epiderm

121 y purport to use, the antecedents that their de-escalation intervention is targeting, its key attribu

122 ith breast cancer, particularly if treatment de-escalation is being considered for small or node nega

123 Axillary de-escalation is motivated by a desire to reduce harm of

124 INTERPRETATION: TKI de-escalation is safe for most patients with excellent r

125 g a robust evidence-base for the efficacy of de-escalation is striking and must, at least in part, be

126 De-escalation is the recommended first-line response to

127 ox regression for the impact of EDE and late de-escalation (LDE) on 30-day all-cause mortality.

128 nsivists and infectious disease specialists, de-escalation may actually be possible in <50% of cases.

129 alation (median rate ratio, 1.11; P=0.36) or de-escalation (median rate ratio, 1.10; P=0.20) compared

130 Our electronic de-escalation metric demonstrated variation among hospit

131 ing endothelial cell level at day 8, using a de-escalation model.

132 hip programs (ASPs) promote the principle of de-escalation: moving from broad to narrow spectrum agen

133 hip programs (ASPs) promote the principle of de-escalation: moving from broad- to narrow-spectrum age

134 A propensity score (PS) for EDE vs no de-escalation (NDE) was calculated.

135 Among 39 226 eligible admissions, de-escalation occurred in 14 138 (36%), escalation in 51

136 Among 39,226 eligible admissions, de-escalation occurred in 14,138 (36%), escalation in 5,

137 scalation than the control group (34%), with de-escalation occurring sooner in the BCID group (48 h;

138 most commonly reported environment in which de-escalation occurs, and nursing the disciplinary group

139 Conclusions Escalation or de-escalation of AAMs was less common than continuation

140 - and low-risk groups for intensification or de-escalation of adjuvant chemotherapy.

141 De-escalation of adjuvant therapy is feasible for select

142 gible for target trial emulations evaluating de-escalation of anti-methicillin-resistant Staphylococc

143 calation from combination therapy, and 43 on de-escalation of anti-TNF agents, including 3 during pre

144 t antibiotic modification (ie, escalation or de-escalation of antibiotics against Gram-negative and G

145 ontrol group (p=0.015); median time to first de-escalation of antibiotics against Gram-negative organ

146 Median time to first de-escalation of antibiotics against Gram-positive organ

147 e VAP so that appropriate discontinuation or de-escalation of antimicrobial therapy can be initiated

148 is a paucity of data on the effect of early de-escalation of antimicrobial therapy on rates of Clost

149 De-escalation of antiplatelet therapy at the time of BAR

150 De-escalation of antiplatelet therapy at the time of BAR

151 Early de-escalation of APBL using clinical risk assessment too

152 ents were grouped into three categories: (1) de-escalation of beta-lactam spectrum score (BLSS), (2)

153 anel could have led to earlier escalation or de-escalation of beta-lactam therapy in a majority of pa

154 matic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs

155 lity of treatment-weighted cohort exposed to de-escalation of BSA vs continuation at day 4.

156 a tumor could identify patients eligible for de-escalation of chemoradiotherapy while maintaining tre

157 rminant of poor outcomes in this population, de-escalation of chemotherapy intensity might be feasibl

158 Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent

159 De-escalation of DAPT intensity can reduce bleeding with

160 De-escalation of empiric antibiotics and adequacy of the

161 In this study, de-escalation of empiric BSA therapy at day 4 was associ

162 s change in antimicrobial prescriptions (ie, de-escalation of empirical antimicrobial therapy or comm

163 De-escalation of empirical vancomycin to definitive beta

164 mucosal and pharyngeal-related DLT required de-escalation of gemcitabine dose in successive patient

165 the main issues and challenges regarding the de-escalation of ICBs in patients with NSCLC, focusing o

166 Personalized escalation and de-escalation of immune checkpoint inhibitor (ICI) regim

167 ovide an opportunity to design trials toward de-escalation of local therapy.

168 However, guidance regarding de-escalation of medical therapy is lacking.

169 umber of studies are currently investigating de-escalation of radiation therapy in patients with a lo

170 e-negative breast cancer), and the basis for de-escalation of surgery in the breast and axilla and fo

171 De-escalation of surgical interventions in the setting o

172 Our findings are of great importance for de-escalation of surgical strategies.

173 e HER2-positive breast cancer, escalation or de-escalation of systemic therapy is a controversial top

174 oming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS sc

175 ctions for GN bacteremia to facilitate early de-escalation of therapy without compromising adequacy o

176 ntiresorptive therapy once per month without de-escalation of therapy.

177 lized, and policy-informed, with emphasis on de-escalation of therapy.

178 -limiting myelosuppression persisted despite de-escalation of TOPO to 0.3 mg/m(2)/d and use of G-CSF.

179 The hypothesis that de-escalation of treatment intensity for patients with p

180 ese patients could be candidates for further de-escalation of treatment, to avoid overtreatment and t

181 To clarify the concept of de-escalation of violence and aggression as described wi

182 Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from

183 The effects of de-escalation on primary outcomes were estimated by diff

184 n of omitting adjuvant radiotherapy (partial de-escalation) on the basis of a pCR.

185 It is not known whether we can expand de-escalation options for younger patients by incorporat

186 ithin 1 day of KKIN PCR report, resulting in de-escalation or antimicrobial optimization.

187 Initial antibacterial therapy and antibiotic de-escalation or discontinuation focused on patients wit

188 of the 18 patients and was managed with dose de-escalation or discontinuation per standard of care.

189 isease, as well as the possible strategy for de-escalation or discontinuation therapy.

190 from Gram stain to appropriate antimicrobial de-escalation or escalation was shortest in the rmPCR/AS

191 econdary outcomes were time to antimicrobial de-escalation or escalation, length of stay (LOS), morta

192 omarkers that may be used to guide treatment de-escalation or imaging surveillance are lacking.

193 marker that could be used to guide treatment de-escalation or imaging surveillance for patients with

194 There were no dose de-escalations or dose-limiting toxicities and nivolumab

195 In a dose de-escalation phase 1 design, patients received ramuciru

196 lticenter, open-label, 3 + 3 dose-escalation/de-escalation phase 1 trial studying IMA203, an autologo

197 the rationale for continuing antibiotics and de-escalation plans.

198 nation in either adults or toddlers, and age de-escalation proceeded accordingly.

199 alation rates ranged from 2-35% and hospital de-escalation rate quartile was not significantly associ

200 Diagnoses with lower de-escalation rates included intra-abdominal (23%) and s

201 Hospital de-escalation rates ranged from 2-35% and hospital de-es

202 De-escalation rates varied between hospitals (median, 29

203 spital day 4 following negative cultures and de-escalation rates varied widely between hospitals.

204 g patients at lowest risk for mortality, the de-escalation rates were <50%.

205 een studied, nor has the effect of treatment de-escalation rather than outright cessation.

206 In ctDNA-negative patients, de-escalation reduced oxaliplatin use (34.8% versus 88.6

207 Aggressive RT de-escalation resulted in locoregional tumor control rat

208 wer days of antibiotics to day 14 (anti-MRSA de-escalation: risk ratio [RR], 0.91; 95% CI, 0.89-0.93;

209 calation was shortest in the rmPCR/AS group (de-escalation: rmPCR/AS 21 hours, control 34 hours, rmPC

210 shorter length of hospitalization (anti-MRSA de-escalation: RR, 0.88; 95% CI, 0.85-0.92; anti-PSA de-

211 ation: RR, 0.88; 95% CI, 0.85-0.92; anti-PSA de-escalation: RR, 0.91; 0.88-0.93).

212 atio [RR], 0.91; 95% CI, 0.89-0.93; anti-PSA de-escalation: RR, 0.91; 95% CI, 0.88-0.93) and shorter

213 igned by using a traditional dose-escalation/de-escalation rule based on observed toxicities in the c

214 nt cornerstone of breast cancer therapy, but de-escalation schemes have become the standard of care.

215 a scheme specifying when and how therapeutic de-escalation should be performed was constructed.

216 decision making has the potential to advise (de)escalation strategies.

217 ence the safety and efficacy of antiplatelet de-escalation strategies after PCI, particularly those i

218 re the comparative effects of different DAPT de-escalation strategies among females and males.

219 ibacterial prophylaxis, initial therapy, and de-escalation strategies are summarised in this Policy R

220 Several de-escalation strategies for human papillomavirus (HPV)-

221 Dual antiplatelet therapy (DAPT) de-escalation strategies improve outcomes after percutan

222 s are exploring the feasibility of treatment de-escalation strategies in patients with a negative int

223 De-escalation strategies were grouped into (1) DAPT disc

224 naive, and thus can be used for chemotherapy de-escalation strategies, is unknown.

225 DC treatment lays the groundwork for further de-escalation strategies.

226 r OS, supporting its use in response-adapted de-escalation strategies.

227 nding trials with interim dose escalation or de-escalation strategies.

228 als investigating (neo)adjuvant chemotherapy de-escalation strategies.

229 rasugrel-treated patients, a genotype-guided de-escalation strategy can reduce bleeding risk, whereas

230 A dose de-escalation strategy identified recommended pralatrexa

231 A de-escalation strategy with anti-EGFR monotherapy repres

232 ROP in at least 1 eye from 2 sequential dose de-escalation studies of low-dose IVB (0.25 mg, 0.125 mg

233 s suitable for use in potential chemotherapy de-escalation studies.

234 Phase 1b was an open-label, dose de-escalation study to identify a safe dose of rilotumum

235 under suboptimal conditions, an antigen dose de-escalation study was performed in the presence of eit

236 linical trial was a single-center 3 + 3 dose de-escalation study with an effectiveness expansion coho

237 matched unrelated marrow and PBMCs in a dose de-escalation study.

238 olled in a masked, multicenter, phase 1 dose de-escalation study.

239 aff response and environmental influences on de-escalation success and failure.

240 aff, patient and environmental influences on de-escalation success or failure.

241 De-escalation techniques are recommended to manage viole

242 To obtain staff descriptions of de-escalation techniques currently used in mental health

243 s to the implementation and effectiveness of de-escalation techniques in practice are not well unders

244 ntly conceptualised by staff as a feature of de-escalation techniques, yet, there was evidence of a l

245 se of restrictive practices through enhanced de-escalation techniques.

246 2%) groups had higher rates of antimicrobial de-escalation than the control group (34%), with de-esca

247 ausea) improved during the first 3 months of de-escalation, though not thereafter.

248 ight not benefit all patients, and treatment de-escalation through omission of chemotherapy has shown

249 Dose escalation to 200 mg/m(2) and de-escalation to 110 mg/m(2) were allowed based on adver

250 t 60 mg/m(2) subcutaneously on days 1-5 with de-escalation to 45 mg/m2 in case of dose limiting toxic

251 of iadademstat at 90 mug/m(2) per day (with de-escalation to 60 mug/m(2) per day and escalation up t

252 he starting dose of 12 mg/m(2)/d resulted in de-escalation to 8 mg/m(2)/d and subsequent re-escalatio

253 dence that, compared with 12 months of DAPT, de-escalation to ticagrelor monotherapy does not increas

254 was to summarise the evidence comparing DAPT de-escalation to ticagrelor monotherapy versus continuin

255 was myelosuppressive, requiring several dose de-escalations to 2 mg/m(2), the dose suggested for phas

256 De-escalation took place a median of 78 days (IQR 31-92)

257 ay provide means for rational escalation and de-escalation treatment strategies in HER2-positive brea

258 Multiple DAPT de-escalation treatment strategies, including switching

259 st prospective trial comparing 2 neoadjuvant de-escalation treatments in HR-positive/ERBB2-positive E

260 trolled, open-label, curative-intent therapy de-escalation trial, a higher radiotherapy dose was asso

261 cardiac involvement were enrolled in a dose de-escalation trial.

262 s analysis and proving MINDACT as a positive de-escalation trial.

263 e selection of good prognosis patients for a de-escalation trial.

264 Many radiation and chemotherapy de-escalation trials are underway.

265 Considerations for the development of de-escalation trials for systemic adjuvant treatment, in

266 To address this, several treatment de-escalation trials have been conducted, but only a few

267 ulated radiation therapy, immunotherapy, and de-escalation trials, might allow for improved treatment

268 or forgoing specific therapies in treatment de-escalation trials.

269 -prevention trials and provide rationale for de-escalation trials.

270 ving the design and implementation of future de-escalation trials.

271 8-day cycle in a rolling 6 study design with de-escalation upon dose-limiting toxicities to establish

272 rvention and control sites, before and after de-escalation, using a before-after-control-impact time-

273 De-escalation varied among hospitals (median 37%, range

274 De-escalation varied among hospitals (median, 37%; range

275 In the stepwise de-escalation versus standard groups, BARC type 3 or 5 b

276 rrelates of AAM escalation (vs no change) or de-escalation (vs no change) were evaluated using multiv

277 De-escalation was applied in 93 episodes (43%), escalati

278 De-escalation was associated with a decreased risk of ne

279 De-escalation was associated with a reduced proportion o

280 De-escalation was associated with lower adjusted risks f

281 a new class of AAM or dose increase, whereas de-escalation was defined as a reduction in the number o

282 De-escalation was defined as reduction in either the num

283 De-escalation was defined as stopping anti-MRSA and anti

284 De-escalation was defined as stopping both empiric drugs

285 Due to toxicity, a dose de-escalation was made to EOC + P DL-1 (epirubicin 50 mg

286 De-escalation was more common in medium, large, and teac

287 clinically significant perforation), whereas de-escalation was more frequent among patients taking mo

288 No dose de-escalation was needed.

289 coated balloons exclusively, a stepwise DAPT de-escalation was non-inferior to 12 month DAPT for net

290 De-escalation was not associated with clinical failure o

291 De-escalation was possible for patients receiving weekly

292 Proposed theories or models of de-escalation were assessed against quality criteria.

293 Additionally, anti-MRSA and anti-PSA de-escalation were associated with fewer days of antibio

294 In weighted analyses, anti-MRSA and anti-PSA de-escalation were associated with similar 90-day mortal

295 Five theories of de-escalation were proposed; while each was adequate in

296 Information about the specific attributes of de-escalation were subject to thematic analysis.

297 ssessment of antimicrobial therapy daily for de-escalation, when appropriate (1B); infection source c

298 alteration could potentially guide treatment de-escalation, which is especially relevant for Black pa

299 ntibiotic de-escalation, and associations of de-escalation with outcomes.

300 ntibiotic de-escalation, and associations of de-escalation with outcomes.